Therapeutic Drug Monitoring Market By Drugs (Antibiotics, Cardiac Drugs, Antiepileptics, Bronchodilators, Immunosuppressants, Anti-cancer drugs, Psychiatric drugs, Antiarrythmics, Others); By Products (Consumables, Equipment (Immunoassay Analyzers, Chromatography and MS Detectors, Others) Others); By Technology (Fluorescence Immunoassay, Chemiluminescent Immunoassays, Radioimmunassay, Thin Layer Chromatography, Radio immuno assay, Enzyme immune assay, Spectrophotometry and Fluorimetry, Others); By End Users(Hospitals & Clinics, Diagnostic centers, Research institutes, Others); By Region (U.S., Canada, Mexico, Rest of North America, The UK, France, Germany, Italy, Spain, Nordic Countries (Denmark, Finland, Iceland, Sweden, Norway), Benelux Union (Belgium, the Netherlands, Luxembourg), Rest of Europe, China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia (Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia), Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa,Brazil, Argentina, Rest of Latin America) – Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2019 - 2027
Industry Trends
Therapeutic drug monitoring (TDM) can be termed as the management of the drug regimen based on the concentration of the drug in the serum, plasma or whole blood of the patient. In TDM, a precise and reliable measure of the plasma concentration of a specific medicine is obtained initially. Later, the sample is used for the interpretation of the concentration-effect relationship in patients. This data is then used for the calculation of a personalized dose adjustment for the patient. Therapeutic drug monitoring is generally used with drugs having features like marked pharmacokinetic (movement of drug through body) variability, narrow therapeutic index (ratio that compares the blood concentration at which a drug becomes toxic), amongst others. TDM is witnessing high demand amidst the growth of chronic diseases worldwide. World Health Organization states that chronic diseases such as cardiovascular diseases, respiratory diseases, cancer, diabetes, etc., will account for 60% of global disease burden, and 73% of all deaths globally by 2020. These diseases mostly require continuous medications. This, in turn creates a need for maintaining a steady concentration of drugs in the blood streams of the patient throughout the patient's life. Therapeutic drug monitoring assist medical professionals in identifying appropriate drug dosage for patients affected by chronic diseases. It is also essential for the determination of immunosuppressive drug concentrations in treatment of immune-mediated diseases. Thus, the significant increase in chronic diseases which require constant drug concentration monitoring is driving the growth of the therapeutic drug monitoring market across the globe.
Clinical assessment of patients through therapeutic drug monitoring provides information with respect to the improvement post drug intake, and possible drug-related side effects. However, the lack of awareness regarding the benefits of drug monitoring amongst the low and middle income population in the developing countries is hindering the growth of the global therapeutic drug monitoring market. World Health Organization states that reduced survival years due to medication-related errors in developing nations is almost twice as that of the developed nations. Other factors such as inaccuracies in the measurement of plasma concentration values and the lack of technical skills that are necessary for the interpretation of plasma concentration value in human beings are few factors restraining the growth of the global therapeutic drug monitoring market.
Government bodies and health organizations around the globe are initiating programs to spread awareness on drug therapy management for reducing medication-associated health hazards amongst individuals. Organizations across the world are also encouraging the use of therapeutic drug monitoring. For instance, World Health Organization launched a program named Global Patient Safety Challenge on Medication Safety in March 2017. The program is aimed at improving the medicine prescription and consumption methods, as well as creating awareness among patients about the risks associated with the improper use of medication. Similarly, government bodies in Australia, the U.S, India, Malaysia, etc., are promoting the adoption of therapeutic drug monitoring. Therefore, these government initiatives that aid in the familiarization of TDM are anticipated to propel the growth of the global therapeutic drug monitoring market in the coming years.
The recent outbreak of COVID-19 pandemic has led to more than 33.5 million reported cases of infection, and death of around 1 million people across the globe. The pandemic has created a high demand for an effective plan for the creation of a vaccine as well as the discovery of drugs that aid in patient recovery. Researchers are experimenting with a variety of potential drugs that are suitable for COVID-19 recovery. For instance, companies such as Astellas, AstraZeneca, Johnson & Johnson, Novartis, amongst others are conducting research to develop effective medicine for Coronavirus infection. Assessmet-based studies of dose tolerance and dose response in patients are an integral part of the drug development process, and require insightful analysis for dosage optimization. Pharmacokinetic and pharmacodynamics studies are also involved in these phases. They are performed through therapeutic drug monitoring. Thus, the demand for analytical studies of pharmaceutical drugs under development to curb the COVID-19 outbreak is expected to boost the growth of global therapeutic drug monitoring market.
Drugs Outlook:
Studies show that cardiovascular diseases are the leading cause of deaths across the globe, with over 17.9 million lives being claimed each year. The number of diseases are expected to increase in the coming years as a result of added stress amongst individuals. The prevalence of cardiovascular diseases has inflated the demand for cardiac drugs for the treatment conditions such as of angina, arrhythmias and congestive failure. Digoxin or Lanxin is a commonly prescribed drug for congestive failure and it is therapeutically monitored for assessing the pharmacokinetics of patients. Thus, sudden growth in the number of cardiovascular diseases, coupled with the need for analysing the toxicity of drugs used in the treatment is driving the share of cardiac drugs in the global therapeutic drug monitoring market.
Technology Outlook:
Based on the type of technology, fluorescence immunoassay accounted for a significant share in the global therapeutic drug monitoring market in 2018. This can be attributed to its high specificity, accuracy and precision. The technology is used in numerous medical care facilities for the measurement of various compounds, especially pharmaceutical drugs in patients. Fluorescence immunoassays with features like low cost light source compatibility, stable fluorophores, stable solid state light detectors and microchips for processing data are being developed by the market participants. For instance, the fluorescence immunoassays of Quidel Corporation has microprocessors which facilitate accurate testing and reduce misinterpretation of data. Thus, higher levels of accuracy, reliability and ease of handling are few of the factors driving the share of fluorescence immunoassay technology in the therapeutic drug monitoring market across the globe.
Regional Outlook:
North America region registered the highest share in global therapeutic drug monitoring market in 2018, owing to the high presence of geriatric population. Statistics of the U.S. Census Bureau stated more than 54 million Americans were 65 years of age or older, in July 2019. The geriatric population is highly prone to adverse drug reactions, drug interactions and chronic medical conditions, which drastically increases the challenges associated with drug therapy management. Thus, the high risk of drug toxicity among geriatric population is creating demand for therapeutic drug monitoring to verify patient compliance with drug regimens in the North American region.
In terms of revenue, global therapeutic drug monitoring market was valued at US$ 1465.62 Mn in 2018 and is anticipated to grow at a CAGR of 6.27% over the forecast period. The study analyses the market in terms of revenue across all the major regions, which have been bifurcated into countries.
Global Therapeutic Drug Monitoring Market Revenue & Forecast, (US$ Million), 2015 – 2027
Competitive Landscape
The report provides both, qualitative and quantitative research of therapeutic drug monitoring market, as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contracts adopted by these major market participants are also recognized and analyzed in the report. For each company, the report studies their global presence, competitors, service offerings and specification amongst others.
Some of the players operating in the therapeutic drug monitoring market are Abbot, Agilent Technologies, apDia Group, ARK Diagnostics, Inc., Beckman Coulter, Inc., bioMérieux S.A., Bio-Rad Laboratories, Inc., BioTeZ Berlin Buch GmbH, BÜHLMANN, Chromsystems Instruments & Chemicals GmbH, Exagen, Inc., F. Hoffmann-La Roche Ltd, Hamilton Company, Immundiagnostik AG, Quest Diagnostics Incorporated, Randox Laboratories Ltd., R-Biopharm AG, SEKISUI CHEMICAL CO., LTD., Siemens Healthcare Private Limited, THERADIAG, Thermo Fisher Scientific Inc. and UTAKamongst others.
Global Therapeutic Drug MonitoringMarket:
By Drugs
- Antibiotics
- Cardiac Drugs
- Antiepileptics
- Bronchodilators
- Immunosuppressants
- Anti-cancer drugs
- Psychiatric drugs
- Antiarrythmics
- Others
By Products
- Consumables
- Equipment
- Immunoassay Analyzers
- Chromatography and MS Detectors
- Others
- Others
By Technology
- Fluorescence Immunoassay
- Chemiluminescent Immunoassays
- Radioimmunassay
- Thin Layer Chromatography
- Radio immuno assay
- Enzyme immune assay
- Spectrophotometry and Fluorimetry
- Others
By End Users
- Hospitals & Clinics
- Diagnostic centers
- Research institutes
- Others
By Geography
- North America
- US
- Canada
- Mexico
- Rest of North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
Table of Contents
1. Market
Scope
1.1. Market
Segmentation
1.2. Years
Considered
1.2.1. Historic
Years: 2013 - 2017
1.2.2. Base
Year: 2018
1.2.3. Forecast
Years: 2019 – 2027
2. Key Target
Audiences
3. Research
Methodology
3.1. Primary
Research
3.1.1. Research
Questionnaire
3.1.2. Global
Percentage Breakdown
3.1.3. Primary
Interviews: Key Opinion Leaders (KOLs)
3.2. Secondary
Research
3.2.1. Paid
Databases
3.2.2. Secondary
Sources
3.3. Market
Size Estimates
3.3.1. Top-Down
Approach
3.3.2. Bottom-Up
Approach
3.4. Data
Triangulation Methodology
3.5. Research
Assumptions
4. Recommendations
and Insights from AMI’s Perspective**
5. Holistic
Overview of Therapeutic Drug Monitoring Market
6. Market
Synopsis: Therapeutic Drug Monitoring
Market
7. Therapeutic
Drug Monitoring Market Analysis: Qualitative Perspective
7.1. Introduction
7.1.1. Product
Definition
7.1.2. Industry
Development
7.2. Market Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Opportunities
7.3. Trends in
Therapeutic Drug Monitoring Market
7.4. Market
Determinants Radar Chart
7.5. Macro-Economic
and Micro-Economic Indicators: Therapeutic Drug Monitoring Market
7.6. Analysis
on Impact of COVID-19 on Therapeutic Drug Monitoring Market
8. Global
Therapeutic Drug Monitoring Market Analysis and Forecasts, 2019 – 2027
8.1. Overview
8.1.1. Global
Therapeutic Drug Monitoring Market Revenue (US$ Mn)
8.2. Global
Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Drugs
8.2.1. Antibiotics
8.2.1.1. Definition
8.2.1.2. Market
Estimation and Penetration, 2013 – 2018
8.2.1.3. Market
Forecast, 2019 – 2027
8.2.1.4. Compound
Annual Growth Rate (CAGR)
8.2.1.5. Regional
Bifurcation
8.2.1.5.1. North
America
8.2.1.5.1.1. Market
Estimation, 2013 – 2018
8.2.1.5.1.2. Market
Forecast, 2019 – 2027
8.2.1.5.2. Europe
8.2.1.5.2.1. Market
Estimation, 2013 – 2018
8.2.1.5.2.2. Market
Forecast, 2019 – 2027
8.2.1.5.3. Asia
Pacific
8.2.1.5.3.1. Market
Estimation, 2013 – 2018
8.2.1.5.3.2. Market
Forecast, 2019 – 2027
8.2.1.5.4. Middle
East and Africa
8.2.1.5.4.1. Market
Estimation, 2013 – 2018
8.2.1.5.4.2. Market
Forecast, 2019 – 2027
8.2.1.5.5. Latin
America
8.2.1.5.5.1. Market
Estimation, 2013 – 2018
8.2.1.5.5.2. Market
Forecast, 2019 – 2027
8.2.2. Cardiac
Drugs
8.2.2.1. Definition
8.2.2.2. Market
Estimation and Penetration, 2013 – 2018
8.2.2.3. Market
Forecast, 2019 – 2027
8.2.2.4. Compound
Annual Growth Rate (CAGR)
8.2.2.5. Regional
Bifurcation
8.2.2.5.1. North
America
8.2.2.5.1.1. Market
Estimation, 2013 – 2018
8.2.2.5.1.2. Market
Forecast, 2019 – 2027
8.2.2.5.2. Europe
8.2.2.5.2.1. Market
Estimation, 2013 – 2018
8.2.2.5.2.2. Market
Forecast, 2019 – 2027
8.2.2.5.3. Asia
Pacific
8.2.2.5.3.1. Market
Estimation, 2013 – 2018
8.2.2.5.3.2. Market
Forecast, 2019 – 2027
8.2.2.5.4. Middle
East and Africa
8.2.2.5.4.1. Market
Estimation, 2013 – 2018
8.2.2.5.4.2. Market
Forecast, 2019 – 2027
8.2.2.5.5. Latin
America
8.2.2.5.5.1. Market
Estimation, 2013 – 2018
8.2.2.5.5.2. Market
Forecast, 2019 – 2027
8.2.3. Antiepileptics
8.2.3.1. Definition
8.2.3.2. Market
Estimation and Penetration, 2013 – 2018
8.2.3.3. Market
Forecast, 2019 – 2027
8.2.3.4. Compound
Annual Growth Rate (CAGR)
8.2.3.5. Regional
Bifurcation
8.2.3.5.1. North
America
8.2.3.5.1.1. Market
Estimation, 2013 – 2018
8.2.3.5.1.2. Market
Forecast, 2019 – 2027
8.2.3.5.2. Europe
8.2.3.5.2.1. Market
Estimation, 2013 – 2018
8.2.3.5.2.2. Market
Forecast, 2019 – 2027
8.2.3.5.3. Asia
Pacific
8.2.3.5.3.1. Market
Estimation, 2013 – 2018
8.2.3.5.3.2. Market
Forecast, 2019 – 2027
8.2.3.5.4. Middle
East and Africa
8.2.3.5.4.1. Market
Estimation, 2013 – 2018
8.2.3.5.4.2. Market
Forecast, 2019 – 2027
8.2.3.5.5. Latin
America
8.2.3.5.5.1. Market
Estimation, 2013 – 2018
8.2.3.5.5.2. Market
Forecast, 2019 – 2027
8.2.4. Bronchodilators
8.2.4.1. Definition
8.2.4.2. Market
Estimation and Penetration, 2013 – 2018
8.2.4.3. Market
Forecast, 2019 – 2027
8.2.4.4. Compound
Annual Growth Rate (CAGR)
8.2.4.5. Regional
Bifurcation
8.2.4.5.1. North
America
8.2.4.5.1.1. Market
Estimation, 2013 – 2018
8.2.4.5.1.2. Market
Forecast, 2019 – 2027
8.2.4.5.2. Europe
8.2.4.5.2.1. Market
Estimation, 2013 – 2018
8.2.4.5.2.2. Market
Forecast, 2019 – 2027
8.2.4.5.3. Asia
Pacific
8.2.4.5.3.1. Market
Estimation, 2013 – 2018
8.2.4.5.3.2. Market
Forecast, 2019 – 2027
8.2.4.5.4. Middle
East and Africa
8.2.4.5.4.1. Market
Estimation, 2013 – 2018
8.2.4.5.4.2. Market
Forecast, 2019 – 2027
8.2.4.5.5. Latin
America
8.2.4.5.5.1. Market
Estimation, 2013 – 2018
8.2.4.5.5.2. Market
Forecast, 2019 – 2027
8.2.5. Immunosuppressants
8.2.5.1. Definition
8.2.5.2. Market
Estimation and Penetration, 2013 – 2018
8.2.5.3. Market
Forecast, 2019 – 2027
8.2.5.4. Compound
Annual Growth Rate (CAGR)
8.2.5.5. Regional
Bifurcation
8.2.5.5.1. North
America
8.2.5.5.1.1. Market
Estimation, 2013 – 2018
8.2.5.5.1.2. Market
Forecast, 2019 – 2027
8.2.5.5.2. Europe
8.2.5.5.2.1. Market
Estimation, 2013 – 2018
8.2.5.5.2.2. Market
Forecast, 2019 – 2027
8.2.5.5.3. Asia
Pacific
8.2.5.5.3.1. Market
Estimation, 2013 – 2018
8.2.5.5.3.2. Market
Forecast, 2019 – 2027
8.2.5.5.4. Middle
East and Africa
8.2.5.5.4.1. Market
Estimation, 2013 – 2018
8.2.5.5.4.2. Market
Forecast, 2019 – 2027
8.2.5.5.5. Latin
America
8.2.5.5.5.1. Market
Estimation, 2013 – 2018
8.2.5.5.5.2. Market
Forecast, 2019 – 2027
8.2.6. Anti-cancer
drugs
8.2.6.1. Definition
8.2.6.2. Market
Estimation and Penetration, 2013 – 2018
8.2.6.3. Market
Forecast, 2019 – 2027
8.2.6.4. Compound
Annual Growth Rate (CAGR)
8.2.6.5. Regional
Bifurcation
8.2.6.5.1. North
America
8.2.6.5.1.1. Market
Estimation, 2013 – 2018
8.2.6.5.1.2. Market
Forecast, 2019 – 2027
8.2.6.5.2. Europe
8.2.6.5.2.1. Market
Estimation, 2013 – 2018
8.2.6.5.2.2. Market
Forecast, 2019 – 2027
8.2.6.5.3. Asia
Pacific
8.2.6.5.3.1. Market
Estimation, 2013 – 2018
8.2.6.5.3.2. Market
Forecast, 2019 – 2027
8.2.6.5.4. Middle
East and Africa
8.2.6.5.4.1. Market
Estimation, 2013 – 2018
8.2.6.5.4.2. Market
Forecast, 2019 – 2027
8.2.6.5.5. Latin
America
8.2.6.5.5.1. Market
Estimation, 2013 – 2018
8.2.6.5.5.2. Market
Forecast, 2019 – 2027
8.2.7. Psychiatric
drugs
8.2.7.1. Definition
8.2.7.2. Market
Estimation and Penetration, 2013 – 2018
8.2.7.3. Market
Forecast, 2019 – 2027
8.2.7.4. Compound
Annual Growth Rate (CAGR)
8.2.7.5. Regional
Bifurcation
8.2.7.5.1. North
America
8.2.7.5.1.1. Market
Estimation, 2013 – 2018
8.2.7.5.1.2. Market
Forecast, 2019 – 2027
8.2.7.5.2. Europe
8.2.7.5.2.1. Market
Estimation, 2013 – 2018
8.2.7.5.2.2. Market
Forecast, 2019 – 2027
8.2.7.5.3. Asia
Pacific
8.2.7.5.3.1. Market
Estimation, 2013 – 2018
8.2.7.5.3.2. Market
Forecast, 2019 – 2027
8.2.7.5.4. Middle
East and Africa
8.2.7.5.4.1. Market
Estimation, 2013 – 2018
8.2.7.5.4.2. Market
Forecast, 2019 – 2027
8.2.7.5.5. Latin
America
8.2.7.5.5.1. Market
Estimation, 2013 – 2018
8.2.7.5.5.2. Market
Forecast, 2019 – 2027
8.2.8. Antiarrythmics
8.2.8.1. Definition
8.2.8.2. Market
Estimation and Penetration, 2013 – 2018
8.2.8.3. Market
Forecast, 2019 – 2027
8.2.8.4. Compound
Annual Growth Rate (CAGR)
8.2.8.5. Regional
Bifurcation
8.2.8.5.1. North
America
8.2.8.5.1.1. Market
Estimation, 2013 – 2018
8.2.8.5.1.2. Market
Forecast, 2019 – 2027
8.2.8.5.2. Europe
8.2.8.5.2.1. Market
Estimation, 2013 – 2018
8.2.8.5.2.2. Market
Forecast, 2019 – 2027
8.2.8.5.3. Asia
Pacific
8.2.8.5.3.1. Market
Estimation, 2013 – 2018
8.2.8.5.3.2. Market
Forecast, 2019 – 2027
8.2.8.5.4. Middle
East and Africa
8.2.8.5.4.1. Market
Estimation, 2013 – 2018
8.2.8.5.4.2. Market
Forecast, 2019 – 2027
8.2.8.5.5. Latin
America
8.2.8.5.5.1. Market
Estimation, 2013 – 2018
8.2.8.5.5.2. Market
Forecast, 2019 – 2027
8.2.9. Others
8.2.9.1. Definition
8.2.9.2. Market
Estimation and Penetration, 2013 – 2018
8.2.9.3. Market
Forecast, 2019 – 2027
8.2.9.4. Compound
Annual Growth Rate (CAGR)
8.2.9.5. Regional
Bifurcation
8.2.9.5.1. North
America
8.2.9.5.1.1. Market
Estimation, 2013 – 2018
8.2.9.5.1.2. Market
Forecast, 2019 – 2027
8.2.9.5.2. Europe
8.2.9.5.2.1. Market
Estimation, 2013 – 2018
8.2.9.5.2.2. Market
Forecast, 2019 – 2027
8.2.9.5.3. Asia
Pacific
8.2.9.5.3.1. Market
Estimation, 2013 – 2018
8.2.9.5.3.2. Market
Forecast, 2019 – 2027
8.2.9.5.4. Middle
East and Africa
8.2.9.5.4.1. Market
Estimation, 2013 – 2018
8.2.9.5.4.2. Market
Forecast, 2019 – 2027
8.2.9.5.5. Latin
America
8.2.9.5.5.1. Market
Estimation, 2013 – 2018
8.2.9.5.5.2. Market
Forecast, 2019 – 2027
8.3. Key
Segment for Channeling Investments
8.3.1. By Drugs
9. Global
Therapeutic Drug Monitoring Market Analysis and Forecasts, 2019 – 2027
9.1. Overview
9.2. Global
Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Products
9.2.1. Consumables
9.2.1.1. Definition
9.2.1.2. Market
Estimation and Penetration, 2013 – 2018
9.2.1.3. Market
Forecast, 2019 – 2027
9.2.1.4. Compound
Annual Growth Rate (CAGR)
9.2.1.5. Regional
Bifurcation
9.2.1.5.1. North
America
9.2.1.5.1.1. Market
Estimation, 2013 – 2018
9.2.1.5.1.2. Market
Forecast, 2019 – 2027
9.2.1.5.2. Europe
9.2.1.5.2.1. Market
Estimation, 2013 – 2018
9.2.1.5.2.2. Market
Forecast, 2019 – 2027
9.2.1.5.3. Asia
Pacific
9.2.1.5.3.1. Market
Estimation, 2013 – 2018
9.2.1.5.3.2. Market
Forecast, 2019 – 2027
9.2.1.5.4. Middle
East and Africa
9.2.1.5.4.1. Market
Estimation, 2013 – 2018
9.2.1.5.4.2. Market
Forecast, 2019 – 2027
9.2.1.5.5. Latin
America
9.2.1.5.5.1. Market
Estimation, 2013 – 2018
9.2.1.5.5.2. Market
Forecast, 2019 – 2027
9.2.2. Equipment
(Definition, Market Estimation and Penetration, 2013 – 2018, Market Estimation
(2013 – 2018), Market Forecast (2019 – 2027), Compound Annual Growth Rate
(CAGR), Regional Bifurcation (North America, Europe, Asia Pacific, Middle East
and Africa, Latin America) and Information on Immunoassay Analyzers,
Chromatography and MS Detectors, Others)
9.2.2.1. Immunoassay
Analyzers
9.2.2.2. Chromatography
and MS Detectors
9.2.2.3. Others
9.2.3. Others
9.2.3.1. Definition
9.2.3.2. Market
Estimation and Penetration, 2013 – 2018
9.2.3.3. Market
Forecast, 2019 – 2027
9.2.3.4. Compound
Annual Growth Rate (CAGR)
9.2.3.5. Regional
Bifurcation
9.2.3.5.1. North
America
9.2.3.5.1.1. Market
Estimation, 2013 – 2018
9.2.3.5.1.2. Market
Forecast, 2019 – 2027
9.2.3.5.2. Europe
9.2.3.5.2.1. Market
Estimation, 2013 – 2018
9.2.3.5.2.2. Market
Forecast, 2019 – 2027
9.2.3.5.3. Asia
Pacific
9.2.3.5.3.1. Market
Estimation, 2013 – 2018
9.2.3.5.3.2. Market
Forecast, 2019 – 2027
9.2.3.5.4. Middle
East and Africa
9.2.3.5.4.1. Market
Estimation, 2013 – 2018
9.2.3.5.4.2. Market
Forecast, 2019 – 2027
9.2.3.5.5. Latin
America
9.2.3.5.5.1. Market
Estimation, 2013 – 2018
9.2.3.5.5.2. Market
Forecast, 2019 – 2027
9.3. Key
Segment for Channeling Investments
9.3.1. By
Products
10. Global
Therapeutic Drug Monitoring Market Analysis and Forecasts, 2019 – 2027
10.1. Overview
10.2. Global
Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By
Technology
10.2.1. Fluorescence
Immunoassay
10.2.1.1. Definition
10.2.1.2. Market
Estimation and Penetration, 2013 – 2018
10.2.1.3. Market
Forecast, 2019 – 2027
10.2.1.4. Compound
Annual Growth Rate (CAGR)
10.2.1.5. Regional
Bifurcation
10.2.1.5.1. North
America
10.2.1.5.1.1. Market
Estimation, 2013 – 2018
10.2.1.5.1.2. Market
Forecast, 2019 – 2027
10.2.1.5.2. Europe
10.2.1.5.2.1. Market
Estimation, 2013 – 2018
10.2.1.5.2.2. Market
Forecast, 2019 – 2027
10.2.1.5.3. Asia
Pacific
10.2.1.5.3.1. Market
Estimation, 2013 – 2018
10.2.1.5.3.2. Market
Forecast, 2019 – 2027
10.2.1.5.4. Middle
East and Africa
10.2.1.5.4.1. Market
Estimation, 2013 – 2018
10.2.1.5.4.2. Market
Forecast, 2019 – 2027
10.2.1.5.5. Latin
America
10.2.1.5.5.1. Market
Estimation, 2013 – 2018
10.2.1.5.5.2. Market
Forecast, 2019 – 2027
10.2.2. Chemiluminescent
Immunoassays
10.2.2.1. Definition
10.2.2.2. Market
Estimation and Penetration, 2013 – 2018
10.2.2.3. Market
Forecast, 2019 – 2027
10.2.2.4. Compound
Annual Growth Rate (CAGR)
10.2.2.5. Regional
Bifurcation
10.2.2.5.1. North
America
10.2.2.5.1.1. Market
Estimation, 2013 – 2018
10.2.2.5.1.2. Market
Forecast, 2019 – 2027
10.2.2.5.2. Europe
10.2.2.5.2.1. Market
Estimation, 2013 – 2018
10.2.2.5.2.2. Market
Forecast, 2019 – 2027
10.2.2.5.3. Asia
Pacific
10.2.2.5.3.1. Market
Estimation, 2013 – 2018
10.2.2.5.3.2. Market
Forecast, 2019 – 2027
10.2.2.5.4. Middle
East and Africa
10.2.2.5.4.1. Market
Estimation, 2013 – 2018
10.2.2.5.4.2. Market
Forecast, 2019 – 2027
10.2.2.5.5. Latin
America
10.2.2.5.5.1. Market
Estimation, 2013 – 2018
10.2.2.5.5.2. Market
Forecast, 2019 – 2027
10.2.3. Radioimmunassay
10.2.3.1. Definition
10.2.3.2. Market
Estimation and Penetration, 2013 – 2018
10.2.3.3. Market
Forecast, 2019 – 2027
10.2.3.4. Compound
Annual Growth Rate (CAGR)
10.2.3.5. Regional
Bifurcation
10.2.3.5.1. North
America
10.2.3.5.1.1. Market
Estimation, 2013 – 2018
10.2.3.5.1.2. Market
Forecast, 2019 – 2027
10.2.3.5.2. Europe
10.2.3.5.2.1. Market
Estimation, 2013 – 2018
10.2.3.5.2.2. Market
Forecast, 2019 – 2027
10.2.3.5.3. Asia
Pacific
10.2.3.5.3.1. Market
Estimation, 2013 – 2018
10.2.3.5.3.2. Market
Forecast, 2019 – 2027
10.2.3.5.4. Middle
East and Africa
10.2.3.5.4.1. Market
Estimation, 2013 – 2018
10.2.3.5.4.2. Market
Forecast, 2019 – 2027
10.2.3.5.5. Latin
America
10.2.3.5.5.1. Market
Estimation, 2013 – 2018
10.2.3.5.5.2. Market
Forecast, 2019 – 2027
10.2.4. Thin
Layer Chromatography
10.2.4.1. Definition
10.2.4.2. Market
Estimation and Penetration, 2013 – 2018
10.2.4.3. Market
Forecast, 2019 – 2027
10.2.4.4. Compound
Annual Growth Rate (CAGR)
10.2.4.5. Regional
Bifurcation
10.2.4.5.1. North
America
10.2.4.5.1.1. Market
Estimation, 2013 – 2018
10.2.4.5.1.2. Market
Forecast, 2019 – 2027
10.2.4.5.2. Europe
10.2.4.5.2.1. Market
Estimation, 2013 – 2018
10.2.4.5.2.2. Market
Forecast, 2019 – 2027
10.2.4.5.3. Asia
Pacific
10.2.4.5.3.1. Market
Estimation, 2013 – 2018
10.2.4.5.3.2. Market
Forecast, 2019 – 2027
10.2.4.5.4. Middle
East and Africa
10.2.4.5.4.1. Market
Estimation, 2013 – 2018
10.2.4.5.4.2. Market
Forecast, 2019 – 2027
10.2.4.5.5. Latin
America
10.2.4.5.5.1. Market
Estimation, 2013 – 2018
10.2.4.5.5.2. Market
Forecast, 2019 – 2027
10.2.5. Radio
immuno assay
10.2.5.1. Definition
10.2.5.2. Market
Estimation and Penetration, 2013 – 2018
10.2.5.3. Market
Forecast, 2019 – 2027
10.2.5.4. Compound
Annual Growth Rate (CAGR)
10.2.5.5. Regional
Bifurcation
10.2.5.5.1. North
America
10.2.5.5.1.1. Market
Estimation, 2013 – 2018
10.2.5.5.1.2. Market
Forecast, 2019 – 2027
10.2.5.5.2. Europe
10.2.5.5.2.1. Market
Estimation, 2013 – 2018
10.2.5.5.2.2. Market
Forecast, 2019 – 2027
10.2.5.5.3. Asia
Pacific
10.2.5.5.3.1. Market
Estimation, 2013 – 2018
10.2.5.5.3.2. Market
Forecast, 2019 – 2027
10.2.5.5.4. Middle
East and Africa
10.2.5.5.4.1. Market
Estimation, 2013 – 2018
10.2.5.5.4.2. Market
Forecast, 2019 – 2027
10.2.5.5.5. Latin
America
10.2.5.5.5.1. Market
Estimation, 2013 – 2018
10.2.5.5.5.2. Market
Forecast, 2019 – 2027
10.2.6. Enzyme
immune assay
10.2.6.1. Definition
10.2.6.2. Market
Estimation and Penetration, 2013 – 2018
10.2.6.3. Market
Forecast, 2019 – 2027
10.2.6.4. Compound
Annual Growth Rate (CAGR)
10.2.6.5. Regional
Bifurcation
10.2.6.5.1. North
America
10.2.6.5.1.1. Market
Estimation, 2013 – 2018
10.2.6.5.1.2. Market
Forecast, 2019 – 2027
10.2.6.5.2. Europe
10.2.6.5.2.1. Market
Estimation, 2013 – 2018
10.2.6.5.2.2. Market
Forecast, 2019 – 2027
10.2.6.5.3. Asia
Pacific
10.2.6.5.3.1. Market
Estimation, 2013 – 2018
10.2.6.5.3.2. Market
Forecast, 2019 – 2027
10.2.6.5.4. Middle
East and Africa
10.2.6.5.4.1. Market
Estimation, 2013 – 2018
10.2.6.5.4.2. Market
Forecast, 2019 – 2027
10.2.6.5.5. Latin
America
10.2.6.5.5.1. Market
Estimation, 2013 – 2018
10.2.6.5.5.2. Market
Forecast, 2019 – 2027
10.2.7. Spectrophotometry
and Fluorimetry
10.2.7.1. Definition
10.2.7.2. Market
Estimation and Penetration, 2013 – 2018
10.2.7.3. Market
Forecast, 2019 – 2027
10.2.7.4. Compound
Annual Growth Rate (CAGR)
10.2.7.5. Regional
Bifurcation
10.2.7.5.1. North
America
10.2.7.5.1.1. Market
Estimation, 2013 – 2018
10.2.7.5.1.2. Market
Forecast, 2019 – 2027
10.2.7.5.2. Europe
10.2.7.5.2.1. Market
Estimation, 2013 – 2018
10.2.7.5.2.2. Market
Forecast, 2019 – 2027
10.2.7.5.3. Asia
Pacific
10.2.7.5.3.1. Market
Estimation, 2013 – 2018
10.2.7.5.3.2. Market
Forecast, 2019 – 2027
10.2.7.5.4. Middle
East and Africa
10.2.7.5.4.1. Market
Estimation, 2013 – 2018
10.2.7.5.4.2. Market
Forecast, 2019 – 2027
10.2.7.5.5. Latin
America
10.2.7.5.5.1. Market
Estimation, 2013 – 2018
10.2.7.5.5.2. Market
Forecast, 2019 – 2027
10.2.8. Others
10.2.8.1. Definition
10.2.8.2. Market
Estimation and Penetration, 2013 – 2018
10.2.8.3. Market
Forecast, 2019 – 2027
10.2.8.4. Compound
Annual Growth Rate (CAGR)
10.2.8.5. Regional
Bifurcation
10.2.8.5.1. North
America
10.2.8.5.1.1. Market
Estimation, 2013 – 2018
10.2.8.5.1.2. Market
Forecast, 2019 – 2027
10.2.8.5.2. Europe
10.2.8.5.2.1. Market
Estimation, 2013 – 2018
10.2.8.5.2.2. Market
Forecast, 2019 – 2027
10.2.8.5.3. Asia
Pacific
10.2.8.5.3.1. Market
Estimation, 2013 – 2018
10.2.8.5.3.2. Market
Forecast, 2019 – 2027
10.2.8.5.4. Middle
East and Africa
10.2.8.5.4.1. Market
Estimation, 2013 – 2018
10.2.8.5.4.2. Market
Forecast, 2019 – 2027
10.2.8.5.5. Latin
America
10.2.8.5.5.1. Market
Estimation, 2013 – 2018
10.2.8.5.5.2. Market
Forecast, 2019 – 2027
10.3. Key
Segment for Channeling Investments
10.3.1. By
Technology
11. Global
Therapeutic Drug Monitoring Market Analysis and Forecasts, 2019 – 2027
11.1. Overview
11.2. Global
Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By End Users
11.2.1. Hospitals
and Clinics
11.2.1.1. Definition
11.2.1.2. Market
Estimation and Penetration, 2013 – 2018
11.2.1.3. Market
Forecast, 2019 – 2027
11.2.1.4. Compound
Annual Growth Rate (CAGR)
11.2.1.5. Regional
Bifurcation
11.2.1.5.1. North
America
11.2.1.5.1.1. Market
Estimation, 2013 – 2018
11.2.1.5.1.2. Market
Forecast, 2019 – 2027
11.2.1.5.2. Europe
11.2.1.5.2.1. Market
Estimation, 2013 – 2018
11.2.1.5.2.2. Market
Forecast, 2019 – 2027
11.2.1.5.3. Asia
Pacific
11.2.1.5.3.1. Market
Estimation, 2013 – 2018
11.2.1.5.3.2. Market
Forecast, 2019 – 2027
11.2.1.5.4. Middle
East and Africa
11.2.1.5.4.1. Market
Estimation, 2013 – 2018
11.2.1.5.4.2. Market
Forecast, 2019 – 2027
11.2.1.5.5. Latin
America
11.2.1.5.5.1. Market
Estimation, 2013 – 2018
11.2.1.5.5.2. Market
Forecast, 2019 – 2027
11.2.2. Diagnostic
centers
11.2.2.1. Definition
11.2.2.2. Market
Estimation and Penetration, 2013 – 2018
11.2.2.3. Market
Forecast, 2019 – 2027
11.2.2.4. Compound
Annual Growth Rate (CAGR)
11.2.2.5. Regional
Bifurcation
11.2.2.5.1. North
America
11.2.2.5.1.1. Market
Estimation, 2013 – 2018
11.2.2.5.1.2. Market
Forecast, 2019 – 2027
11.2.2.5.2. Europe
11.2.2.5.2.1. Market
Estimation, 2013 – 2018
11.2.2.5.2.2. Market
Forecast, 2019 – 2027
11.2.2.5.3. Asia
Pacific
11.2.2.5.3.1. Market
Estimation, 2013 – 2018
11.2.2.5.3.2. Market
Forecast, 2019 – 2027
11.2.2.5.4. Middle
East and Africa
11.2.2.5.4.1. Market
Estimation, 2013 – 2018
11.2.2.5.4.2. Market
Forecast, 2019 – 2027
11.2.2.5.5. Latin
America
11.2.2.5.5.1. Market
Estimation, 2013 – 2018
11.2.2.5.5.2. Market
Forecast, 2019 – 2027
11.2.3. Research
institutes
11.2.3.1. Definition
11.2.3.2. Market
Estimation and Penetration, 2013 – 2018
11.2.3.3. Market
Forecast, 2019 – 2027
11.2.3.4. Compound
Annual Growth Rate (CAGR)
11.2.3.5. Regional
Bifurcation
11.2.3.5.1. North
America
11.2.3.5.1.1. Market
Estimation, 2013 – 2018
11.2.3.5.1.2. Market
Forecast, 2019 – 2027
11.2.3.5.2. Europe
11.2.3.5.2.1. Market
Estimation, 2013 – 2018
11.2.3.5.2.2. Market
Forecast, 2019 – 2027
11.2.3.5.3. Asia
Pacific
11.2.3.5.3.1. Market
Estimation, 2013 – 2018
11.2.3.5.3.2. Market
Forecast, 2019 – 2027
11.2.3.5.4. Middle
East and Africa
11.2.3.5.4.1. Market
Estimation, 2013 – 2018
11.2.3.5.4.2. Market
Forecast, 2019 – 2027
11.2.3.5.5. Latin
America
11.2.3.5.5.1. Market
Estimation, 2013 – 2018
11.2.3.5.5.2. Market
Forecast, 2019 – 2027
11.2.4. Others
11.2.4.1. Definition
11.2.4.2. Market
Estimation and Penetration, 2013 – 2018
11.2.4.3. Market
Forecast, 2019 – 2027
11.2.4.4. Compound
Annual Growth Rate (CAGR)
11.2.4.5. Regional
Bifurcation
11.2.4.5.1. North
America
11.2.4.5.1.1. Market
Estimation, 2013 – 2018
11.2.4.5.1.2. Market
Forecast, 2019 – 2027
11.2.4.5.2. Europe
11.2.4.5.2.1. Market
Estimation, 2013 – 2018
11.2.4.5.2.2. Market
Forecast, 2019 – 2027
11.2.4.5.3. Asia
Pacific
11.2.4.5.3.1. Market
Estimation, 2013 – 2018
11.2.4.5.3.2. Market
Forecast, 2019 – 2027
11.2.4.5.4. Middle
East and Africa
11.2.4.5.4.1. Market
Estimation, 2013 – 2018
11.2.4.5.4.2. Market
Forecast, 2019 – 2027
11.2.4.5.5. Latin
America
11.2.4.5.5.1. Market
Estimation, 2013 – 2018
11.2.4.5.5.2. Market
Forecast, 2019 – 2027
11.3. Key
Segment for Channeling Investments
11.3.1. By End Users
12. North
America Therapeutic Drug Monitoring Market Analysis and Forecasts, 2019 - 2027
12.1. Overview
12.1.1. North
America Therapeutic Drug Monitoring Market Revenue (US$ Mn)
12.2. North
America Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By
Drugs
12.2.1. Antibiotics
12.2.2. Cardiac
Drugs
12.2.3. Antiepileptics
12.2.4. Bronchodilators
12.2.5. Immunosuppressants
12.2.6. Anti-cancer
drugs
12.2.7. Psychiatric
drugs
12.2.8. Antiarrythmics
12.2.9. Others
12.3. North
America Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By
Products
12.3.1. Consumables
12.3.2. Equipment
12.3.2.1. Immunoassay
Analyzers
12.3.2.2. Chromatography
and MS Detectors
12.3.2.3. Others
12.3.3. Others
12.4. North
America Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By
Technology
12.4.1. Fluorescence
Immunoassay
12.4.2. Chemiluminescent
Immunoassays
12.4.3. Radioimmunassay
12.4.4. Thin
Layer Chromatography
12.4.5. Radio
immuno assay
12.4.6. Enzyme
immune assay
12.4.7. Spectrophotometry
and Fluorimetry
12.4.8. Others
12.5. North
America Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By
End Users
12.5.1. Hospitals
and Clinics
12.5.2. Diagnostic
centers
12.5.3. Research
institutes
12.5.4. Others
12.6. North America
Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Country
12.6.1. U.S
12.6.1.1. U.S
Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Drugs
12.6.1.1.1. Antibiotics
12.6.1.1.2. Cardiac
Drugs
12.6.1.1.3. Antiepileptics
12.6.1.1.4. Bronchodilators
12.6.1.1.5. Immunosuppressants
12.6.1.1.6. Anti-cancer
drugs
12.6.1.1.7. Psychiatric
drugs
12.6.1.1.8. Antiarrythmics
12.6.1.1.9. Others
12.6.1.2. U.S
Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Products
12.6.1.2.1. Consumables
12.6.1.2.2. Equipment
12.6.1.2.2.1. Immunoassay
Analyzers
12.6.1.2.2.2. Chromatography
and MS Detectors
12.6.1.2.2.3. Others
12.6.1.2.3. Others
12.6.1.3. U.S
Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By
Technology
12.6.1.3.1. Fluorescence
Immunoassay
12.6.1.3.2. Chemiluminescent
Immunoassays
12.6.1.3.3. Radioimmunassay
12.6.1.3.4. Thin
Layer Chromatography
12.6.1.3.5. Radio
immuno assay
12.6.1.3.6. Enzyme
immune assay
12.6.1.3.7. Spectrophotometry
and Fluorimetry
12.6.1.3.8. Others
12.6.1.4. U.S
Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By End Users
12.6.1.4.1. Hospitals
and Clinics
12.6.1.4.2. Diagnostic
centers
12.6.1.4.3. Research
institutes
12.6.1.4.4. Others
12.6.2. Canada
12.6.2.1. Canada
Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Drugs
12.6.2.1.1. Antibiotics
12.6.2.1.2. Cardiac
Drugs
12.6.2.1.3. Antiepileptics
12.6.2.1.4. Bronchodilators
12.6.2.1.5. Immunosuppressants
12.6.2.1.6. Anti-cancer
drugs
12.6.2.1.7. Psychiatric
drugs
12.6.2.1.8. Antiarrythmics
12.6.2.1.9. Others
12.6.2.2. Canada
Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Products
12.6.2.2.1. Consumables
12.6.2.2.2. Equipment
12.6.2.2.2.1. Immunoassay
Analyzers
12.6.2.2.2.2. Chromatography
and MS Detectors
12.6.2.2.2.3. Others
12.6.2.2.3. Others
12.6.2.3. Canada
Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By
Technology
12.6.2.3.1. Fluorescence
Immunoassay
12.6.2.3.2. Chemiluminescent
Immunoassays
12.6.2.3.3. Radioimmunassay
12.6.2.3.4. Thin
Layer Chromatography
12.6.2.3.5. Radio
immuno assay
12.6.2.3.6. Enzyme
immune assay
12.6.2.3.7. Spectrophotometry
and Fluorimetry
12.6.2.3.8. Others
12.6.2.4. Canada
Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By End Users
12.6.2.4.1. Hospitals
and Clinics
12.6.2.4.2. Diagnostic
centers
12.6.2.4.3. Research
institutes
12.6.2.4.4. Others
12.6.3. Mexico
12.6.3.1. Mexico
Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Drugs
12.6.3.1.1. Antibiotics
12.6.3.1.2. Cardiac
Drugs
12.6.3.1.3. Antiepileptics
12.6.3.1.4. Bronchodilators
12.6.3.1.5. Immunosuppressants
12.6.3.1.6. Anti-cancer
drugs
12.6.3.1.7. Psychiatric
drugs
12.6.3.1.8. Antiarrythmics
12.6.3.1.9. Others
12.6.3.2. Mexico
Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Products
12.6.3.2.1. Consumables
12.6.3.2.2. Equipment
12.6.3.2.2.1. Immunoassay
Analyzers
12.6.3.2.2.2. Chromatography
and MS Detectors
12.6.3.2.2.3. Others
12.6.3.2.3. Others
12.6.3.3. Mexico
Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By
Technology
12.6.3.3.1. Fluorescence
Immunoassay
12.6.3.3.2. Chemiluminescent
Immunoassays
12.6.3.3.3. Radioimmunassay
12.6.3.3.4. Thin
Layer Chromatography
12.6.3.3.5. Radio
immuno assay
12.6.3.3.6. Enzyme
immune assay
12.6.3.3.7. Spectrophotometry
and Fluorimetry
12.6.3.3.8. Others
12.6.3.4. Mexico
Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By End Users
12.6.3.4.1. Hospitals
and Clinics
12.6.3.4.2. Diagnostic
centers
12.6.3.4.3. Research
institutes
12.6.3.4.4. Others
12.6.4. Rest of
North America
12.6.4.1. Rest
of North America Therapeutic Drug Monitoring Market Revenue (US$ Mn) and
Forecasts, By Drugs
12.6.4.1.1. Antibiotics
12.6.4.1.2. Cardiac
Drugs
12.6.4.1.3. Antiepileptics
12.6.4.1.4. Bronchodilators
12.6.4.1.5. Immunosuppressants
12.6.4.1.6. Anti-cancer
drugs
12.6.4.1.7. Psychiatric
drugs
12.6.4.1.8. Antiarrythmics
12.6.4.1.9. Others
12.6.4.2. Rest
of North America Therapeutic Drug Monitoring Market Revenue (US$ Mn) and
Forecasts, By Products
12.6.4.2.1. Consumables
12.6.4.2.2. Equipment
12.6.4.2.2.1. Immunoassay
Analyzers
12.6.4.2.2.2. Chromatography
and MS Detectors
12.6.4.2.2.3. Others
12.6.4.2.3. Others
12.6.4.3. Rest
of North America Therapeutic Drug Monitoring Market Revenue (US$ Mn) and
Forecasts, By Technology
12.6.4.3.1. Fluorescence
Immunoassay
12.6.4.3.2. Chemiluminescent
Immunoassays
12.6.4.3.3. Radioimmunassay
12.6.4.3.4. Thin
Layer Chromatography
12.6.4.3.5. Radio
immuno assay
12.6.4.3.6. Enzyme
immune assay
12.6.4.3.7. Spectrophotometry
and Fluorimetry
12.6.4.3.8. Others
12.6.4.4. Rest
of North America Therapeutic Drug Monitoring Market Revenue (US$ Mn) and
Forecasts, By End Users
12.6.4.4.1. Hospitals
and Clinics
12.6.4.4.2. Diagnostic
centers
12.6.4.4.3. Research
institutes
12.6.4.4.4. Others
12.7. Key
Segment for Channeling Investments
12.7.1. By
Country
12.7.2. By
Drugs
12.7.3. By
Products
12.7.4. By
Technology
12.7.5. By End
Users
13. Europe
Therapeutic Drug Monitoring Market Analysis and Forecasts, 2019 - 2027
13.1. Overview
13.1.1. Europe
Therapeutic Drug Monitoring Market Revenue (US$ Mn)
13.2. Europe
Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Drugs
13.2.1. Antibiotics
13.2.2. Cardiac
Drugs
13.2.3. Antiepileptics
13.2.4. Bronchodilators
13.2.5. Immunosuppressants
13.2.6. Anti-cancer
drugs
13.2.7. Psychiatric
drugs
13.2.8. Antiarrythmics
13.2.9. Others
13.3. Europe
Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Products
13.3.1. Consumables
13.3.2. Equipment
13.3.2.1. Immunoassay
Analyzers
13.3.2.2. Chromatography
and MS Detectors
13.3.2.3. Others
13.3.3. Others
13.4. Europe
Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By
Technology
13.4.1. Fluorescence
Immunoassay
13.4.2. Chemiluminescent
Immunoassays
13.4.3. Radioimmunassay
13.4.4. Thin
Layer Chromatography
13.4.5. Radio
immuno assay
13.4.6. Enzyme
immune assay
13.4.7. Spectrophotometry
and Fluorimetry
13.4.8. Others
13.5. Europe
Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By End Users
13.5.1. Hospitals
and Clinics
13.5.2. Diagnostic
centers
13.5.3. Research
institutes
13.5.4. Others
13.6. Europe
Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Country
13.6.1. France
13.6.1.1. France
Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Drugs
13.6.1.1.1. Antibiotics
13.6.1.1.2. Cardiac
Drugs
13.6.1.1.3. Antiepileptics
13.6.1.1.4. Bronchodilators
13.6.1.1.5. Immunosuppressants
13.6.1.1.6. Anti-cancer
drugs
13.6.1.1.7. Psychiatric
drugs
13.6.1.1.8. Antiarrythmics
13.6.1.1.9. Others
13.6.1.2. France
Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Products
13.6.1.2.1. Consumables
13.6.1.2.2. Equipment
13.6.1.2.2.1. Immunoassay
Analyzers
13.6.1.2.2.2. Chromatography
and MS Detectors
13.6.1.2.2.3. Others
13.6.1.2.3. Others
13.6.1.3. France
Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By
Technology
13.6.1.3.1. Fluorescence
Immunoassay
13.6.1.3.2. Chemiluminescent
Immunoassays
13.6.1.3.3. Radioimmunassay
13.6.1.3.4. Thin
Layer Chromatography
13.6.1.3.5. Radio
immuno assay
13.6.1.3.6. Enzyme
immune assay
13.6.1.3.7. Spectrophotometry
and Fluorimetry
13.6.1.3.8. Others
13.6.1.4. France
Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By End Users
13.6.1.4.1. Hospitals
and Clinics
13.6.1.4.2. Diagnostic
centers
13.6.1.4.3. Research
institutes
13.6.1.4.4. Others
13.6.2. The UK
13.6.2.1. The
UK Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Drugs
13.6.2.1.1. Antibiotics
13.6.2.1.2. Cardiac
Drugs
13.6.2.1.3. Antiepileptics
13.6.2.1.4. Bronchodilators
13.6.2.1.5. Immunosuppressants
13.6.2.1.6. Anti-cancer
drugs
13.6.2.1.7. Psychiatric
drugs
13.6.2.1.8. Antiarrythmics
13.6.2.1.9. Others
13.6.2.2. The
UK Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By
Products
13.6.2.2.1. Consumables
13.6.2.2.2. Equipment
13.6.2.2.2.1. Immunoassay
Analyzers
13.6.2.2.2.2. Chromatography
and MS Detectors
13.6.2.2.2.3. Others
13.6.2.2.3. Others
13.6.2.3. The
UK Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By
Technology
13.6.2.3.1. Fluorescence
Immunoassay
13.6.2.3.2. Chemiluminescent
Immunoassays
13.6.2.3.3. Radioimmunassay
13.6.2.3.4. Thin
Layer Chromatography
13.6.2.3.5. Radio
immuno assay
13.6.2.3.6. Enzyme
immune assay
13.6.2.3.7. Spectrophotometry
and Fluorimetry
13.6.2.3.8. Others
13.6.2.4. The
UK Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By End
Users
13.6.2.4.1. Hospitals
and Clinics
13.6.2.4.2. Diagnostic
centers
13.6.2.4.3. Research
institutes
13.6.2.4.4. Others
13.6.3. Spain
13.6.3.1. Spain
Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Drugs
13.6.3.1.1. Antibiotics
13.6.3.1.2. Cardiac
Drugs
13.6.3.1.3. Antiepileptics
13.6.3.1.4. Bronchodilators
13.6.3.1.5. Immunosuppressants
13.6.3.1.6. Anti-cancer
drugs
13.6.3.1.7. Psychiatric
drugs
13.6.3.1.8. Antiarrythmics
13.6.3.1.9. Others
13.6.3.2. Spain
Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Products
13.6.3.2.1. Consumables
13.6.3.2.2. Equipment
13.6.3.2.2.1. Immunoassay
Analyzers
13.6.3.2.2.2. Chromatography
and MS Detectors
13.6.3.2.2.3. Others
13.6.3.2.3. Others
13.6.3.3. Spain
Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By
Technology
13.6.3.3.1. Fluorescence
Immunoassay
13.6.3.3.2. Chemiluminescent
Immunoassays
13.6.3.3.3. Radioimmunassay
13.6.3.3.4. Thin
Layer Chromatography
13.6.3.3.5. Radio
immuno assay
13.6.3.3.6. Enzyme
immune assay
13.6.3.3.7. Spectrophotometry
and Fluorimetry
13.6.3.3.8. Others
13.6.3.4. Spain
Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By End Users
13.6.3.4.1. Hospitals
and Clinics
13.6.3.4.2. Diagnostic
centers
13.6.3.4.3. Research
institutes
13.6.3.4.4. Others
13.6.4. Germany
13.6.4.1. Germany
Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Drugs
13.6.4.1.1. Antibiotics
13.6.4.1.2. Cardiac
Drugs
13.6.4.1.3. Antiepileptics
13.6.4.1.4. Bronchodilators
13.6.4.1.5. Immunosuppressants
13.6.4.1.6. Anti-cancer
drugs
13.6.4.1.7. Psychiatric
drugs
13.6.4.1.8. Antiarrythmics
13.6.4.1.9. Others
13.6.4.2. Germany
Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Products
13.6.4.2.1. Consumables
13.6.4.2.2. Equipment
13.6.4.2.2.1. Immunoassay
Analyzers
13.6.4.2.2.2. Chromatography
and MS Detectors
13.6.4.2.2.3. Others
13.6.4.2.3. Others
13.6.4.3. Germany
Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By
Technology
13.6.4.3.1. Fluorescence
Immunoassay
13.6.4.3.2. Chemiluminescent
Immunoassays
13.6.4.3.3. Radioimmunassay
13.6.4.3.4. Thin
Layer Chromatography
13.6.4.3.5. Radio
immuno assay
13.6.4.3.6. Enzyme
immune assay
13.6.4.3.7. Spectrophotometry
and Fluorimetry
13.6.4.3.8. Others
13.6.4.4. Germany
Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By End Users
13.6.4.4.1. Hospitals
and Clinics
13.6.4.4.2. Diagnostic
centers
13.6.4.4.3. Research
institutes
13.6.4.4.4. Others
13.6.5. Italy
13.6.5.1. Italy
Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Drugs
13.6.5.1.1. Antibiotics
13.6.5.1.2. Cardiac
Drugs
13.6.5.1.3. Antiepileptics
13.6.5.1.4. Bronchodilators
13.6.5.1.5. Immunosuppressants
13.6.5.1.6. Anti-cancer
drugs
13.6.5.1.7. Psychiatric
drugs
13.6.5.1.8. Antiarrythmics
13.6.5.1.9. Others
13.6.5.2. Italy
Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Products
13.6.5.2.1. Consumables
13.6.5.2.2. Equipment
13.6.5.2.2.1. Immunoassay
Analyzers
13.6.5.2.2.2. Chromatography
and MS Detectors
13.6.5.2.2.3. Others
13.6.5.2.3. Others
13.6.5.3. Italy
Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By
Technology
13.6.5.3.1. Fluorescence
Immunoassay
13.6.5.3.2. Chemiluminescent
Immunoassays
13.6.5.3.3. Radioimmunassay
13.6.5.3.4. Thin
Layer Chromatography
13.6.5.3.5. Radio
immuno assay
13.6.5.3.6. Enzyme
immune assay
13.6.5.3.7. Spectrophotometry
and Fluorimetry
13.6.5.3.8. Others
13.6.5.4. Italy
Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By End Users
13.6.5.4.1. Hospitals
and Clinics
13.6.5.4.2. Diagnostic
centers
13.6.5.4.3. Research
institutes
13.6.5.4.4. Others
13.6.6. Nordic
Countries
13.6.6.1. Nordic
Countries Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By
Drugs
13.6.6.1.1. Antibiotics
13.6.6.1.2. Cardiac
Drugs
13.6.6.1.3. Antiepileptics
13.6.6.1.4. Bronchodilators
13.6.6.1.5. Immunosuppressants
13.6.6.1.6. Anti-cancer
drugs
13.6.6.1.7. Psychiatric
drugs
13.6.6.1.8. Antiarrythmics
13.6.6.1.9. Others
13.6.6.2. Nordic
Countries Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By
Products
13.6.6.2.1. Consumables
13.6.6.2.2. Equipment
13.6.6.2.2.1. Immunoassay
Analyzers
13.6.6.2.2.2. Chromatography
and MS Detectors
13.6.6.2.2.3. Others
13.6.6.2.3. Others
13.6.6.3. Nordic
Countries Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By
Technology
13.6.6.3.1. Fluorescence
Immunoassay
13.6.6.3.2. Chemiluminescent
Immunoassays
13.6.6.3.3. Radioimmunassay
13.6.6.3.4. Thin
Layer Chromatography
13.6.6.3.5. Radio
immuno assay
13.6.6.3.6. Enzyme
immune assay
13.6.6.3.7. Spectrophotometry
and Fluorimetry
13.6.6.3.8. Others
13.6.6.4. Nordic
Countries Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By
End Users
13.6.6.4.1. Hospitals
and Clinics
13.6.6.4.2. Diagnostic
centers
13.6.6.4.3. Research
institutes
13.6.6.4.4. Others
13.6.6.5. Nordic
Countries Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By
Country
13.6.6.5.1. Denmark
13.6.6.5.2. Finland
13.6.6.5.3. Iceland
13.6.6.5.4. Sweden
13.6.6.5.5. Norway
13.6.7. Benelux
Union
13.6.7.1. Benelux
Union Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By
Drugs
13.6.7.1.1. Antibiotics
13.6.7.1.2. Cardiac
Drugs
13.6.7.1.3. Antiepileptics
13.6.7.1.4. Bronchodilators
13.6.7.1.5. Immunosuppressants
13.6.7.1.6. Anti-cancer
drugs
13.6.7.1.7. Psychiatric
drugs
13.6.7.1.8. Antiarrythmics
13.6.7.1.9. Others
13.6.7.2. Benelux
Union Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By
Products
13.6.7.2.1. Consumables
13.6.7.2.2. Equipment
13.6.7.2.2.1. Immunoassay
Analyzers
13.6.7.2.2.2. Chromatography
and MS Detectors
13.6.7.2.2.3. Others
13.6.7.2.3. Others
13.6.7.3. Benelux
Union Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Technology
13.6.7.3.1. Fluorescence
Immunoassay
13.6.7.3.2. Chemiluminescent
Immunoassays
13.6.7.3.3. Radioimmunassay
13.6.7.3.4. Thin
Layer Chromatography
13.6.7.3.5. Radio
immuno assay
13.6.7.3.6. Enzyme
immune assay
13.6.7.3.7. Spectrophotometry
and Fluorimetry
13.6.7.3.8. Others
13.6.7.4. Benelux
Union Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By End
Users
13.6.7.4.1. Hospitals
and Clinics
13.6.7.4.2. Diagnostic
centers
13.6.7.4.3. Research
institutes
13.6.7.4.4. Others
13.6.7.5. Benelux
Union Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By
Country
13.6.7.5.1. Belgium
13.6.7.5.2. The
Netherlands
13.6.7.5.3. Luxembourg
13.6.8. Rest of
Europe
13.6.8.1. Rest
of Europe Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By
Drugs
13.6.8.1.1. Antibiotics
13.6.8.1.2. Cardiac
Drugs
13.6.8.1.3. Antiepileptics
13.6.8.1.4. Bronchodilators
13.6.8.1.5. Immunosuppressants
13.6.8.1.6. Anti-cancer
drugs
13.6.8.1.7. Psychiatric
drugs
13.6.8.1.8. Antiarrythmics
13.6.8.1.9. Others
13.6.8.2. Rest
of Europe Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By
Products
13.6.8.2.1. Consumables
13.6.8.2.2. Equipment
13.6.8.2.2.1. Immunoassay
Analyzers
13.6.8.2.2.2. Chromatography
and MS Detectors
13.6.8.2.2.3. Others
13.6.8.2.3. Others
13.6.8.3. Rest
of Europe Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By
Technology
13.6.8.3.1. Fluorescence
Immunoassay
13.6.8.3.2. Chemiluminescent
Immunoassays
13.6.8.3.3. Radioimmunassay
13.6.8.3.4. Thin
Layer Chromatography
13.6.8.3.5. Radio
immuno assay
13.6.8.3.6. Enzyme
immune assay
13.6.8.3.7. Spectrophotometry
and Fluorimetry
13.6.8.3.8. Others
13.6.8.4. Rest
of Europe Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By
End Users
13.6.8.4.1. Hospitals
and Clinics
13.6.8.4.2. Diagnostic
centers
13.6.8.4.3. Research
institutes
13.6.8.4.4. Others
13.7. Key
Segment for Channeling Investments
13.7.1. By
Country
13.7.2. By
Drugs
13.7.3. By
Products
13.7.4. By
Technology
13.7.5. By End
Users
14. Asia
Pacific Therapeutic Drug Monitoring Market Analysis and Forecasts, 2019 - 2027
14.1. Overview
14.1.1. Asia Pacific
Therapeutic Drug Monitoring Market Revenue (US$ Mn)
14.2. Asia
Pacific Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By
Drugs
14.2.1. Antibiotics
14.2.2. Cardiac
Drugs
14.2.3. Antiepileptics
14.2.4. Bronchodilators
14.2.5. Immunosuppressants
14.2.6. Anti-cancer
drugs
14.2.7. Psychiatric
drugs
14.2.8. Antiarrythmics
14.2.9. Others
14.3. Asia
Pacific Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By
Products
14.3.1. Consumables
14.3.2. Equipment
14.3.2.1. Immunoassay
Analyzers
14.3.2.2. Chromatography
and MS Detectors
14.3.2.3. Others
14.3.3. Others
14.4. Asia
Pacific Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By
Technology
14.4.1. Fluorescence
Immunoassay
14.4.2. Chemiluminescent
Immunoassays
14.4.3. Radioimmunassay
14.4.4. Thin
Layer Chromatography
14.4.5. Radio
immuno assay
14.4.6. Enzyme
immune assay
14.4.7. Spectrophotometry
and Fluorimetry
14.4.8. Others
14.5. Asia
Pacific Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By
End Users
14.5.1. Hospitals
and Clinics
14.5.2. Diagnostic
centers
14.5.3. Research
institutes
14.5.4. Others
14.6. Asia
Pacific Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By
Country
14.6.1. China
14.6.1.1. China
Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Drugs
14.6.1.1.1. Antibiotics
14.6.1.1.2. Cardiac
Drugs
14.6.1.1.3. Antiepileptics
14.6.1.1.4. Bronchodilators
14.6.1.1.5. Immunosuppressants
14.6.1.1.6. Anti-cancer
drugs
14.6.1.1.7. Psychiatric
drugs
14.6.1.1.8. Antiarrythmics
14.6.1.1.9. Others
14.6.1.2. China
Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Products
14.6.1.2.1. Consumables
14.6.1.2.2. Equipment
14.6.1.2.2.1. Immunoassay
Analyzers
14.6.1.2.2.2. Chromatography
and MS Detectors
14.6.1.2.2.3. Others
14.6.1.2.3. Others
14.6.1.3. China
Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By
Technology
14.6.1.3.1. Fluorescence
Immunoassay
14.6.1.3.2. Chemiluminescent
Immunoassays
14.6.1.3.3. Radioimmunassay
14.6.1.3.4. Thin
Layer Chromatography
14.6.1.3.5. Radio
immuno assay
14.6.1.3.6. Enzyme
immune assay
14.6.1.3.7. Spectrophotometry
and Fluorimetry
14.6.1.3.8. Others
14.6.1.4. China
Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By End Users
14.6.1.4.1. Hospitals
and Clinics
14.6.1.4.2. Diagnostic
centers
14.6.1.4.3. Research
institutes
14.6.1.4.4. Others
14.6.2. Japan
14.6.2.1. Japan
Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Drugs
14.6.2.1.1. Antibiotics
14.6.2.1.2. Cardiac
Drugs
14.6.2.1.3. Antiepileptics
14.6.2.1.4. Bronchodilators
14.6.2.1.5. Immunosuppressants
14.6.2.1.6. Anti-cancer
drugs
14.6.2.1.7. Psychiatric
drugs
14.6.2.1.8. Antiarrythmics
14.6.2.1.9. Others
14.6.2.2. Japan
Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Products
14.6.2.2.1. Consumables
14.6.2.2.2. Equipment
14.6.2.2.2.1. Immunoassay
Analyzers
14.6.2.2.2.2. Chromatography
and MS Detectors
14.6.2.2.2.3. Others
14.6.2.2.3. Others
14.6.2.3. Japan
Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By
Technology
14.6.2.3.1. Fluorescence
Immunoassay
14.6.2.3.2. Chemiluminescent
Immunoassays
14.6.2.3.3. Radioimmunassay
14.6.2.3.4. Thin
Layer Chromatography
14.6.2.3.5. Radio
immuno assay
14.6.2.3.6. Enzyme
immune assay
14.6.2.3.7. Spectrophotometry
and Fluorimetry
14.6.2.3.8. Others
14.6.2.4. Japan
Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By End Users
14.6.2.4.1. Hospitals
and Clinics
14.6.2.4.2. Diagnostic
centers
14.6.2.4.3. Research
institutes
14.6.2.4.4. Others
14.6.3. India
14.6.3.1. India
Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Drugs
14.6.3.1.1. Antibiotics
14.6.3.1.2. Cardiac
Drugs
14.6.3.1.3. Antiepileptics
14.6.3.1.4. Bronchodilators
14.6.3.1.5. Immunosuppressants
14.6.3.1.6. Anti-cancer
drugs
14.6.3.1.7. Psychiatric
drugs
14.6.3.1.8. Antiarrythmics
14.6.3.1.9. Others
14.6.3.2. India
Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Products
14.6.3.2.1. Consumables
14.6.3.2.2. Equipment
14.6.3.2.2.1. Immunoassay
Analyzers
14.6.3.2.2.2. Chromatography
and MS Detectors
14.6.3.2.2.3. Others
14.6.3.2.3. Others
14.6.3.3. India
Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By
Technology
14.6.3.3.1. Fluorescence
Immunoassay
14.6.3.3.2. Chemiluminescent
Immunoassays
14.6.3.3.3. Radioimmunassay
14.6.3.3.4. Thin
Layer Chromatography
14.6.3.3.5. Radio
immuno assay
14.6.3.3.6. Enzyme
immune assay
14.6.3.3.7. Spectrophotometry
and Fluorimetry
14.6.3.3.8. Others
14.6.3.4. India
Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By End Users
14.6.3.4.1. Hospitals
and Clinics
14.6.3.4.2. Diagnostic
centers
14.6.3.4.3. Research
institutes
14.6.3.4.4. Others
14.6.4. New
Zealand
14.6.4.1. New
Zealand Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By
Drugs
14.6.4.1.1. Antibiotics
14.6.4.1.2. Cardiac
Drugs
14.6.4.1.3. Antiepileptics
14.6.4.1.4. Bronchodilators
14.6.4.1.5. Immunosuppressants
14.6.4.1.6. Anti-cancer
drugs
14.6.4.1.7. Psychiatric
drugs
14.6.4.1.8. Antiarrythmics
14.6.4.1.9. Others
14.6.4.2. New
Zealand Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By
Products
14.6.4.2.1. Consumables
14.6.4.2.2. Equipment
14.6.4.2.2.1. Immunoassay
Analyzers
14.6.4.2.2.2. Chromatography
and MS Detectors
14.6.4.2.2.3. Others
14.6.4.2.3. Others
14.6.4.3. New
Zealand Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By
Technology
14.6.4.3.1. Fluorescence
Immunoassay
14.6.4.3.2. Chemiluminescent
Immunoassays
14.6.4.3.3. Radioimmunassay
14.6.4.3.4. Thin
Layer Chromatography
14.6.4.3.5. Radio
immuno assay
14.6.4.3.6. Enzyme
immune assay
14.6.4.3.7. Spectrophotometry
and Fluorimetry
14.6.4.3.8. Others
14.6.4.4. New
Zealand Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By
End Users
14.6.4.4.1. Hospitals
and Clinics
14.6.4.4.2. Diagnostic
centers
14.6.4.4.3. Research
institutes
14.6.4.4.4. Others
14.6.5. Australia
14.6.5.1. Australia
Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Drugs
14.6.5.1.1. Antibiotics
14.6.5.1.2. Cardiac
Drugs
14.6.5.1.3. Antiepileptics
14.6.5.1.4. Bronchodilators
14.6.5.1.5. Immunosuppressants
14.6.5.1.6. Anti-cancer
drugs
14.6.5.1.7. Psychiatric
drugs
14.6.5.1.8. Antiarrythmics
14.6.5.1.9. Others
14.6.5.2. Australia
Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Products
14.6.5.2.1. Consumables
14.6.5.2.2. Equipment
14.6.5.2.2.1. Immunoassay
Analyzers
14.6.5.2.2.2. Chromatography
and MS Detectors
14.6.5.2.2.3. Others
14.6.5.2.3. Others
14.6.5.3. Australia
Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By
Technology
14.6.5.3.1. Fluorescence
Immunoassay
14.6.5.3.2. Chemiluminescent
Immunoassays
14.6.5.3.3. Radioimmunassay
14.6.5.3.4. Thin
Layer Chromatography
14.6.5.3.5. Radio
immuno assay
14.6.5.3.6. Enzyme
immune assay
14.6.5.3.7. Spectrophotometry
and Fluorimetry
14.6.5.3.8. Others
14.6.5.4. Australia
Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By End Users
14.6.5.4.1. Hospitals
and Clinics
14.6.5.4.2. Diagnostic
centers
14.6.5.4.3. Research
institutes
14.6.5.4.4. Others
14.6.6. South
Korea
14.6.6.1. South
Korea Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By
Drugs
14.6.6.1.1. Antibiotics
14.6.6.1.2. Cardiac
Drugs
14.6.6.1.3. Antiepileptics
14.6.6.1.4. Bronchodilators
14.6.6.1.5. Immunosuppressants
14.6.6.1.6. Anti-cancer
drugs
14.6.6.1.7. Psychiatric
drugs
14.6.6.1.8. Antiarrythmics
14.6.6.1.9. Others
14.6.6.2. South
Korea Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By
Products
14.6.6.2.1. Consumables
14.6.6.2.2. Equipment
14.6.6.2.2.1. Immunoassay
Analyzers
14.6.6.2.2.2. Chromatography
and MS Detectors
14.6.6.2.2.3. Others
14.6.6.2.3. Others
14.6.6.3. South
Korea Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By
Technology
14.6.6.3.1. Fluorescence
Immunoassay
14.6.6.3.2. Chemiluminescent
Immunoassays
14.6.6.3.3. Radioimmunassay
14.6.6.3.4. Thin
Layer Chromatography
14.6.6.3.5. Radio
immuno assay
14.6.6.3.6. Enzyme
immune assay
14.6.6.3.7. Spectrophotometry
and Fluorimetry
14.6.6.3.8. Others
14.6.6.4. South
Korea Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By End
Users
14.6.6.4.1. Hospitals
and Clinics
14.6.6.4.2. Diagnostic
centers
14.6.6.4.3. Research
institutes
14.6.6.4.4. Others
14.6.7. Southeast
Asia
14.6.7.1. Southeast
Asia Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By
Drugs
14.6.7.1.1. Antibiotics
14.6.7.1.2. Cardiac
Drugs
14.6.7.1.3. Antiepileptics
14.6.7.1.4. Bronchodilators
14.6.7.1.5. Immunosuppressants
14.6.7.1.6. Anti-cancer
drugs
14.6.7.1.7. Psychiatric
drugs
14.6.7.1.8. Antiarrythmics
14.6.7.1.9. Others
14.6.7.2. Southeast
Asia Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By
Products
14.6.7.2.1. Consumables
14.6.7.2.2. Equipment
14.6.7.2.2.1. Immunoassay
Analyzers
14.6.7.2.2.2. Chromatography
and MS Detectors
14.6.7.2.2.3. Others
14.6.7.2.3. Others
14.6.7.3. Southeast
Asia Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By
Technology
14.6.7.3.1. Fluorescence
Immunoassay
14.6.7.3.2. Chemiluminescent
Immunoassays
14.6.7.3.3. Radioimmunassay
14.6.7.3.4. Thin
Layer Chromatography
14.6.7.3.5. Radio
immuno assay
14.6.7.3.6. Enzyme
immune assay
14.6.7.3.7. Spectrophotometry
and Fluorimetry
14.6.7.3.8. Others
14.6.7.4. Southeast
Asia Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By End
Users
14.6.7.4.1. Hospitals
and Clinics
14.6.7.4.2. Diagnostic
centers
14.6.7.4.3. Research
institutes
14.6.7.4.4. Others
14.6.7.5. Southeast
Asia Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By
Country
14.6.7.5.1. Indonesia
14.6.7.5.2. Thailand
14.6.7.5.3. Malaysia
14.6.7.5.4. Singapore
14.6.7.5.5. Rest
of Southeast Asia
14.6.8. Rest of
Asia Pacific
14.6.8.1. Rest
of Asia Pacific Therapeutic Drug Monitoring Market Revenue (US$ Mn) and
Forecasts, By Drugs
14.6.8.1.1. Antibiotics
14.6.8.1.2. Cardiac
Drugs
14.6.8.1.3. Antiepileptics
14.6.8.1.4. Bronchodilators
14.6.8.1.5. Immunosuppressants
14.6.8.1.6. Anti-cancer
drugs
14.6.8.1.7. Psychiatric
drugs
14.6.8.1.8. Antiarrythmics
14.6.8.1.9. Others
14.6.8.2. Rest
of Asia Pacific Therapeutic Drug Monitoring Market Revenue (US$ Mn) and
Forecasts, By Products
14.6.8.2.1. Consumables
14.6.8.2.2. Equipment
14.6.8.2.2.1. Immunoassay
Analyzers
14.6.8.2.2.2. Chromatography
and MS Detectors
14.6.8.2.2.3. Others
14.6.8.2.3. Others
14.6.8.3. Rest
of Asia Pacific Therapeutic Drug Monitoring Market Revenue (US$ Mn) and
Forecasts, By Technology
14.6.8.3.1. Fluorescence
Immunoassay
14.6.8.3.2. Chemiluminescent
Immunoassays
14.6.8.3.3. Radioimmunassay
14.6.8.3.4. Thin
Layer Chromatography
14.6.8.3.5. Radio
immuno assay
14.6.8.3.6. Enzyme
immune assay
14.6.8.3.7. Spectrophotometry
and Fluorimetry
14.6.8.3.8. Others
14.6.8.4. Rest
of Asia Pacific Therapeutic Drug Monitoring Market Revenue (US$ Mn) and
Forecasts, By End Users
14.6.8.4.1. Hospitals
and Clinics
14.6.8.4.2. Diagnostic
centers
14.6.8.4.3. Research
institutes
14.6.8.4.4. Others
14.7. Key
Segment for Channeling Investments
14.7.1. By
Country
14.7.2. By
Drugs
14.7.3. By
Products
14.7.4. By
Technology
14.7.5. By End
Users
15. Middle
East and Africa Therapeutic Drug Monitoring Market Analysis and Forecasts, 2019
- 2027
15.1. Overview
15.1.1. Middle
East and Africa Therapeutic Drug Monitoring Market Revenue (US$ Mn)
15.2. Middle
East and Africa Therapeutic Drug Monitoring Market Revenue (US$ Mn) and
Forecasts, By Drugs
15.2.1. Antibiotics
15.2.2. Cardiac
Drugs
15.2.3. Antiepileptics
15.2.4. Bronchodilators
15.2.5. Immunosuppressants
15.2.6. Anti-cancer
drugs
15.2.7. Psychiatric
drugs
15.2.8. Antiarrythmics
15.2.9. Others
15.3. Middle
East and Africa Therapeutic Drug Monitoring Market Revenue (US$ Mn) and
Forecasts, By Products
15.3.1. Consumables
15.3.2. Equipment
15.3.2.1. Immunoassay
Analyzers
15.3.2.2. Chromatography
and MS Detectors
15.3.2.3. Others
15.3.3. Others
15.4. Middle
East and Africa Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts,
By Technology
15.4.1. Fluorescence
Immunoassay
15.4.2. Chemiluminescent
Immunoassays
15.4.3. Radioimmunassay
15.4.4. Thin
Layer Chromatography
15.4.5. Radio
immuno assay
15.4.6. Enzyme
immune assay
15.4.7. Spectrophotometry
and Fluorimetry
15.4.8. Others
15.5. Middle
East and Africa Therapeutic Drug Monitoring Market Revenue (US$ Mn) and
Forecasts, By End Users
15.5.1. Hospitals
and Clinics
15.5.2. Diagnostic
centers
15.5.3. Research
institutes
15.5.4. Others
15.6. Middle
East and Africa Therapeutic Drug Monitoring Market Revenue (US$ Mn) and
Forecasts, By Country
15.6.1. Saudi
Arabia
15.6.1.1. Saudi
Arabia Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By
Drugs
15.6.1.1.1. Antibiotics
15.6.1.1.2. Cardiac
Drugs
15.6.1.1.3. Antiepileptics
15.6.1.1.4. Bronchodilators
15.6.1.1.5. Immunosuppressants
15.6.1.1.6. Anti-cancer
drugs
15.6.1.1.7. Psychiatric
drugs
15.6.1.1.8. Antiarrythmics
15.6.1.1.9. Others
15.6.1.2. Saudi
Arabia Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By
Products
15.6.1.2.1. Consumables
15.6.1.2.2. Equipment
15.6.1.2.2.1. Immunoassay
Analyzers
15.6.1.2.2.2. Chromatography
and MS Detectors
15.6.1.2.2.3. Others
15.6.1.2.3. Others
15.6.1.3. Saudi
Arabia Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By
Technology
15.6.1.3.1. Fluorescence
Immunoassay
15.6.1.3.2. Chemiluminescent
Immunoassays
15.6.1.3.3. Radioimmunassay
15.6.1.3.4. Thin
Layer Chromatography
15.6.1.3.5. Radio
immuno assay
15.6.1.3.6. Enzyme
immune assay
15.6.1.3.7. Spectrophotometry
and Fluorimetry
15.6.1.3.8. Others
15.6.1.4. Saudi
Arabia Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By
End Users
15.6.1.4.1. Hospitals
and Clinics
15.6.1.4.2. Diagnostic
centers
15.6.1.4.3. Research
institutes
15.6.1.4.4. Others
15.6.2. UAE
15.6.2.1. UAE
Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Drugs
15.6.2.1.1. Antibiotics
15.6.2.1.2. Cardiac
Drugs
15.6.2.1.3. Antiepileptics
15.6.2.1.4. Bronchodilators
15.6.2.1.5. Immunosuppressants
15.6.2.1.6. Anti-cancer
drugs
15.6.2.1.7. Psychiatric
drugs
15.6.2.1.8. Antiarrythmics
15.6.2.1.9. Others
15.6.2.2. UAE
Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Products
15.6.2.2.1. Consumables
15.6.2.2.2. Equipment
15.6.2.2.2.1. Immunoassay
Analyzers
15.6.2.2.2.2. Chromatography
and MS Detectors
15.6.2.2.2.3. Others
15.6.2.2.3. Others
15.6.2.3. UAE
Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Technology
15.6.2.3.1. Fluorescence
Immunoassay
15.6.2.3.2. Chemiluminescent
Immunoassays
15.6.2.3.3. Radioimmunassay
15.6.2.3.4. Thin
Layer Chromatography
15.6.2.3.5. Radio
immuno assay
15.6.2.3.6. Enzyme
immune assay
15.6.2.3.7. Spectrophotometry
and Fluorimetry
15.6.2.3.8. Others
15.6.2.4. UAE
Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By End Users
15.6.2.4.1. Hospitals
and Clinics
15.6.2.4.2. Diagnostic
centers
15.6.2.4.3. Research
institutes
15.6.2.4.4. Others
15.6.3. Egypt
15.6.3.1. Egypt
Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Drugs
15.6.3.1.1. Antibiotics
15.6.3.1.2. Cardiac
Drugs
15.6.3.1.3. Antiepileptics
15.6.3.1.4. Bronchodilators
15.6.3.1.5. Immunosuppressants
15.6.3.1.6. Anti-cancer
drugs
15.6.3.1.7. Psychiatric
drugs
15.6.3.1.8. Antiarrythmics
15.6.3.1.9. Others
15.6.3.2. Egypt
Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Products
15.6.3.2.1. Consumables
15.6.3.2.2. Equipment
15.6.3.2.2.1. Immunoassay
Analyzers
15.6.3.2.2.2. Chromatography
and MS Detectors
15.6.3.2.2.3. Others
15.6.3.2.3. Others
15.6.3.3. Egypt
Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By
Technology
15.6.3.3.1. Fluorescence
Immunoassay
15.6.3.3.2. Chemiluminescent
Immunoassays
15.6.3.3.3. Radioimmunassay
15.6.3.3.4. Thin
Layer Chromatography
15.6.3.3.5. Radio
immuno assay
15.6.3.3.6. Enzyme
immune assay
15.6.3.3.7. Spectrophotometry
and Fluorimetry
15.6.3.3.8. Others
15.6.3.4. Egypt
Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By End Users
15.6.3.4.1. Hospitals
and Clinics
15.6.3.4.2. Diagnostic
centers
15.6.3.4.3. Research
institutes
15.6.3.4.4. Others
15.6.4. Kuwait
15.6.4.1. Kuwait
Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Drugs
15.6.4.1.1. Antibiotics
15.6.4.1.2. Cardiac
Drugs
15.6.4.1.3. Antiepileptics
15.6.4.1.4. Bronchodilators
15.6.4.1.5. Immunosuppressants
15.6.4.1.6. Anti-cancer
drugs
15.6.4.1.7. Psychiatric
drugs
15.6.4.1.8. Antiarrythmics
15.6.4.1.9. Others
15.6.4.2. Kuwait
Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Products
15.6.4.2.1. Consumables
15.6.4.2.2. Equipment
15.6.4.2.2.1. Immunoassay
Analyzers
15.6.4.2.2.2. Chromatography
and MS Detectors
15.6.4.2.2.3. Others
15.6.4.2.3. Others
15.6.4.3. Kuwait
Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By
Technology
15.6.4.3.1. Fluorescence
Immunoassay
15.6.4.3.2. Chemiluminescent
Immunoassays
15.6.4.3.3. Radioimmunassay
15.6.4.3.4. Thin
Layer Chromatography
15.6.4.3.5. Radio
immuno assay
15.6.4.3.6. Enzyme
immune assay
15.6.4.3.7. Spectrophotometry
and Fluorimetry
15.6.4.3.8. Others
15.6.4.4. Kuwait
Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By End Users
15.6.4.4.1. Hospitals
and Clinics
15.6.4.4.2. Diagnostic
centers
15.6.4.4.3. Research
institutes
15.6.4.4.4. Others
15.6.5. South
Africa
15.6.5.1. South
Africa Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By
Drugs
15.6.5.1.1. Antibiotics
15.6.5.1.2. Cardiac
Drugs
15.6.5.1.3. Antiepileptics
15.6.5.1.4. Bronchodilators
15.6.5.1.5. Immunosuppressants
15.6.5.1.6. Anti-cancer
drugs
15.6.5.1.7. Psychiatric
drugs
15.6.5.1.8. Antiarrythmics
15.6.5.1.9. Others
15.6.5.2. South
Africa Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Products
15.6.5.2.1. Consumables
15.6.5.2.2. Equipment
15.6.5.2.2.1. Immunoassay
Analyzers
15.6.5.2.2.2. Chromatography
and MS Detectors
15.6.5.2.2.3. Others
15.6.5.2.3. Others
15.6.5.3. South
Africa Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By
Technology
15.6.5.3.1. Fluorescence
Immunoassay
15.6.5.3.2. Chemiluminescent
Immunoassays
15.6.5.3.3. Radioimmunassay
15.6.5.3.4. Thin
Layer Chromatography
15.6.5.3.5. Radio
immuno assay
15.6.5.3.6. Enzyme
immune assay
15.6.5.3.7. Spectrophotometry
and Fluorimetry
15.6.5.3.8. Others
15.6.5.4. South
Africa Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By
End Users
15.6.5.4.1. Hospitals
and Clinics
15.6.5.4.2. Diagnostic
centers
15.6.5.4.3. Research
institutes
15.6.5.4.4. Others
15.6.6. Rest of
Middle East & Africa
15.6.6.1. Rest
of Middle East & Africa Therapeutic Drug Monitoring Market Revenue (US$ Mn)
and Forecasts, By Drugs
15.6.6.1.1. Antibiotics
15.6.6.1.2. Cardiac
Drugs
15.6.6.1.3. Antiepileptics
15.6.6.1.4. Bronchodilators
15.6.6.1.5. Immunosuppressants
15.6.6.1.6. Anti-cancer
drugs
15.6.6.1.7. Psychiatric
drugs
15.6.6.1.8. Antiarrythmics
15.6.6.1.9. Others
15.6.6.2. Rest
of Middle East & Africa Therapeutic Drug Monitoring Market Revenue (US$ Mn)
and Forecasts, By Products
15.6.6.2.1. Consumables
15.6.6.2.2. Equipment
15.6.6.2.2.1. Immunoassay
Analyzers
15.6.6.2.2.2. Chromatography
and MS Detectors
15.6.6.2.2.3. Others
15.6.6.2.3. Others
15.6.6.3. Rest
of Middle East & Africa Therapeutic Drug Monitoring Market Revenue (US$ Mn)
and Forecasts, By Technology
15.6.6.3.1. Fluorescence
Immunoassay
15.6.6.3.2. Chemiluminescent
Immunoassays
15.6.6.3.3. Radioimmunassay
15.6.6.3.4. Thin
Layer Chromatography
15.6.6.3.5. Radio
immuno assay
15.6.6.3.6. Enzyme
immune assay
15.6.6.3.7. Spectrophotometry
and Fluorimetry
15.6.6.3.8. Others
15.6.6.4. Rest
of Middle East & Africa Therapeutic Drug Monitoring Market Revenue (US$ Mn)
and Forecasts, By End Users
15.6.6.4.1. Hospitals
and Clinics
15.6.6.4.2. Diagnostic
centers
15.6.6.4.3. Research
institutes
15.6.6.4.4. Others
15.7. Key
Segment for Channeling Investments
15.7.1. By
Country
15.7.2. By
Drugs
15.7.3. By
Products
15.7.4. By
Technology
15.7.5. By End
Users
16. Latin
America Therapeutic Drug Monitoring Market Analysis and Forecasts, 2019 - 2027
16.1. Overview
16.1.1. Latin
America Therapeutic Drug Monitoring Market Revenue (US$ Mn)
16.2. Latin
America Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By
Drugs
16.2.1. Antibiotics
16.2.2. Cardiac
Drugs
16.2.3. Antiepileptics
16.2.4. Bronchodilators
16.2.5. Immunosuppressants
16.2.6. Anti-cancer
drugs
16.2.7. Psychiatric
drugs
16.2.8. Antiarrythmics
16.2.9. Others
16.3. Latin
America Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By
Products
16.3.1. Consumables
16.3.2. Equipment
16.3.2.1. Immunoassay
Analyzers
16.3.2.2. Chromatography
and MS Detectors
16.3.2.3. Others
16.3.3. Others
16.4. Latin
America Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By
Technology
16.4.1. Fluorescence
Immunoassay
16.4.2. Chemiluminescent
Immunoassays
16.4.3. Radioimmunassay
16.4.4. Thin
Layer Chromatography
16.4.5. Radio
immuno assay
16.4.6. Enzyme
immune assay
16.4.7. Spectrophotometry
and Fluorimetry
16.4.8. Others
16.5. Latin
America Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By
End Users
16.5.1. Hospitals
and Clinics
16.5.2. Diagnostic
centers
16.5.3. Research
institutes
16.5.4. Others
16.6. Latin
America Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By
Country
16.6.1. Brazil
16.6.1.1. Brazil
Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Drugs
16.6.1.1.1. Antibiotics
16.6.1.1.2. Cardiac
Drugs
16.6.1.1.3. Antiepileptics
16.6.1.1.4. Bronchodilators
16.6.1.1.5. Immunosuppressants
16.6.1.1.6. Anti-cancer
drugs
16.6.1.1.7. Psychiatric
drugs
16.6.1.1.8. Antiarrythmics
16.6.1.1.9. Others
16.6.1.2. Brazil
Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Products
16.6.1.2.1. Consumables
16.6.1.2.2. Equipment
16.6.1.2.2.1. Immunoassay
Analyzers
16.6.1.2.2.2. Chromatography
and MS Detectors
16.6.1.2.2.3. Others
16.6.1.2.3. Others
16.6.1.3. Brazil
Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By
Technology
16.6.1.3.1. Fluorescence
Immunoassay
16.6.1.3.2. Chemiluminescent
Immunoassays
16.6.1.3.3. Radioimmunassay
16.6.1.3.4. Thin
Layer Chromatography
16.6.1.3.5. Radio
immuno assay
16.6.1.3.6. Enzyme
immune assay
16.6.1.3.7. Spectrophotometry
and Fluorimetry
16.6.1.3.8. Others
16.6.1.4. Brazil
Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By End Users
16.6.1.4.1. Hospitals
and Clinics
16.6.1.4.2. Diagnostic
centers
16.6.1.4.3. Research
institutes
16.6.1.4.4. Others
16.6.2. Argentina
16.6.2.1. Argentina
Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Drugs
16.6.2.1.1. Antibiotics
16.6.2.1.2. Cardiac
Drugs
16.6.2.1.3. Antiepileptics
16.6.2.1.4. Bronchodilators
16.6.2.1.5. Immunosuppressants
16.6.2.1.6. Anti-cancer
drugs
16.6.2.1.7. Psychiatric
drugs
16.6.2.1.8. Antiarrythmics
16.6.2.1.9. Others
16.6.2.2. Argentina
Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By Products
16.6.2.2.1. Consumables
16.6.2.2.2. Equipment
16.6.2.2.2.1. Immunoassay
Analyzers
16.6.2.2.2.2. Chromatography
and MS Detectors
16.6.2.2.2.3. Others
16.6.2.2.3. Others
16.6.2.3. Argentina
Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By
Technology
16.6.2.3.1. Fluorescence
Immunoassay
16.6.2.3.2. Chemiluminescent
Immunoassays
16.6.2.3.3. Radioimmunassay
16.6.2.3.4. Thin
Layer Chromatography
16.6.2.3.5. Radio
immuno assay
16.6.2.3.6. Enzyme
immune assay
16.6.2.3.7. Spectrophotometry
and Fluorimetry
16.6.2.3.8. Others
16.6.2.4. Argentina
Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts, By End Users
16.6.2.4.1. Hospitals
and Clinics
16.6.2.4.2. Diagnostic
centers
16.6.2.4.3. Research
institutes
16.6.2.4.4. Others
16.6.3. Rest of
Latin America
16.6.3.1. Rest
of Latin America Therapeutic Drug Monitoring Market Revenue (US$ Mn) and
Forecasts, By Drugs
16.6.3.1.1. Antibiotics
16.6.3.1.2. Cardiac
Drugs
16.6.3.1.3. Antiepileptics
16.6.3.1.4. Bronchodilators
16.6.3.1.5. Immunosuppressants
16.6.3.1.6. Anti-cancer
drugs
16.6.3.1.7. Psychiatric
drugs
16.6.3.1.8. Antiarrythmics
16.6.3.1.9. Others
16.6.3.2. Rest
of Latin America Therapeutic Drug Monitoring Market Revenue (US$ Mn) and
Forecasts, By Products
16.6.3.2.1. Consumables
16.6.3.2.2. Equipment
16.6.3.2.2.1. Immunoassay
Analyzers
16.6.3.2.2.2. Chromatography
and MS Detectors
16.6.3.2.2.3. Others
16.6.3.2.3. Others
16.6.3.3. Rest
of Latin America Therapeutic Drug Monitoring Market Revenue (US$ Mn) and Forecasts,
By Technology
16.6.3.3.1. Fluorescence
Immunoassay
16.6.3.3.2. Chemiluminescent
Immunoassays
16.6.3.3.3. Radioimmunassay
16.6.3.3.4. Thin
Layer Chromatography
16.6.3.3.5. Radio
immuno assay
16.6.3.3.6. Enzyme
immune assay
16.6.3.3.7. Spectrophotometry
and Fluorimetry
16.6.3.3.8. Others
16.6.3.4. Rest
of Latin America Therapeutic Drug Monitoring Market Revenue (US$ Mn) and
Forecasts, By End Users
16.6.3.4.1. Hospitals
and Clinics
16.6.3.4.2. Diagnostic
centers
16.6.3.4.3. Research
institutes
16.6.3.4.4. Others
16.7. Key
Segment for Channeling Investments
16.7.1. By
Country
16.7.2. By
Drugs
16.7.3. By
Products
16.7.4. By
Technology
16.7.5. By End
Users
17. Competitive
Benchmarking
17.1. Market
Share Analysis, 2018
17.2. Global
Presence and Growth Strategies
17.2.1. Mergers
and Acquisitions
17.2.2. Product
Launches
17.2.3. Investments
Trends
17.2.4. R&D
Initiatives
18. Player
Profiles
18.1. Abbot
18.1.1. Company
Details
18.1.2. Company
Overview
18.1.3. Product
Offerings
18.1.4. Key
Developments
18.1.5. Financial
Analysis
18.1.6. SWOT
Analysis
18.1.7. Business
Strategies
18.2. Agilent Technologies
18.2.1. Company
Details
18.2.2. Company
Overview
18.2.3. Product
Offerings
18.2.4. Key
Developments
18.2.5. Financial
Analysis
18.2.6. SWOT
Analysis
18.2.7. Business
Strategies
18.3. apDia Group
18.3.1. Company
Details
18.3.2. Company
Overview
18.3.3. Product
Offerings
18.3.4. Key
Developments
18.3.5. Financial
Analysis
18.3.6. SWOT
Analysis
18.3.7. Business
Strategies
18.4. ARK Diagnostics, Inc.
18.4.1. Company
Details
18.4.2. Company
Overview
18.4.3. Product
Offerings
18.4.4. Key
Developments
18.4.5. Financial
Analysis
18.4.6. SWOT
Analysis
18.4.7. Business
Strategies
18.5. Beckman Coulter, Inc.
18.5.1. Company
Details
18.5.2. Company
Overview
18.5.3. Product
Offerings
18.5.4. Key
Developments
18.5.5. Financial
Analysis
18.5.6. SWOT
Analysis
18.5.7. Business
Strategies
18.6. bioMérieux S.A.
18.6.1. Company
Details
18.6.2. Company
Overview
18.6.3. Product
Offerings
18.6.4. Key
Developments
18.6.5. Financial
Analysis
18.6.6. SWOT
Analysis
18.6.7. Business
Strategies
18.7. Bio-Rad Laboratories, Inc
18.7.1. Company
Details
18.7.2. Company
Overview
18.7.3. Product
Offerings
18.7.4. Key
Developments
18.7.5. Financial
Analysis
18.7.6. SWOT
Analysis
18.7.7. Business
Strategies
18.8. BioTeZ Berlin Buch GmbH
18.8.1. Company
Details
18.8.2. Company
Overview
18.8.3. Product
Offerings
18.8.4. Key
Developments
18.8.5. Financial
Analysis
18.8.6. SWOT
Analysis
18.8.7. Business
Strategies
18.9. BÜHLMANN
18.9.1. Company
Details
18.9.2. Company
Overview
18.9.3. Product
Offerings
18.9.4. Key
Developments
18.9.5. Financial
Analysis
18.9.6. SWOT
Analysis
18.9.7. Business
Strategies
18.10. Chromsystems Instruments &
Chemicals GmbH.
18.10.1. Company
Details
18.10.2. Company
Overview
18.10.3. Product
Offerings
18.10.4. Key
Developments
18.10.5. Financial
Analysis
18.10.6. SWOT
Analysis
18.10.7. Business
Strategies
18.11. Exagen, Inc.
18.11.1. Company
Details
18.11.2. Company
Overview
18.11.3. Product
Offerings
18.11.4. Key
Developments
18.11.5. Financial
Analysis
18.11.6. SWOT
Analysis
18.11.7. Business
Strategies
18.12. F. Hoffmann-La Roche Ltd
18.12.1. Company
Details
18.12.2. Company
Overview
18.12.3. Product
Offerings
18.12.4. Key
Developments
18.12.5. Financial
Analysis
18.12.6. SWOT
Analysis
18.12.7. Business
Strategies
18.13. Hamilton Company
18.13.1. Company
Details
18.13.2. Company
Overview
18.13.3. Product
Offerings
18.13.4. Key
Developments
18.13.5. Financial
Analysis
18.13.6. SWOT
Analysis
18.13.7. Business
Strategies
18.14. Immundiagnostik AG
18.14.1. Company
Details
18.14.2. Company
Overview
18.14.3. Product
Offerings
18.14.4. Key
Developments
18.14.5. Financial
Analysis
18.14.6. SWOT
Analysis
18.14.7. Business
Strategies
18.15. Quest Diagnostics Incorporated
18.15.1. Company
Details
18.15.2. Company
Overview
18.15.3. Product
Offerings
18.15.4. Key
Developments
18.15.5. Financial
Analysis
18.15.6. SWOT
Analysis
18.15.7. Business
Strategies
18.16. Randox Laboratories Ltd.
18.16.1. Company
Details
18.16.2. Company
Overview
18.16.3. Product
Offerings
18.16.4. Key
Developments
18.16.5. Financial
Analysis
18.16.6. SWOT
Analysis
18.16.7. Business
Strategies
18.17. R-Biopharm AG
18.17.1. Company
Details
18.17.2. Company
Overview
18.17.3. Product
Offerings
18.17.4. Key
Developments
18.17.5. Financial
Analysis
18.17.6. SWOT Analysis
18.17.7. Business
Strategies
18.18. SEKISUI CHEMICAL CO., LTD.
18.18.1. Company
Details
18.18.2. Company
Overview
18.18.3. Product
Offerings
18.18.4. Key
Developments
18.18.5. Financial
Analysis
18.18.6. SWOT
Analysis
18.18.7. Business
Strategies
18.19. Siemens Healthcare Private
Limited
18.19.1. Company
Details
18.19.2. Company
Overview
18.19.3. Product
Offerings
18.19.4. Key
Developments
18.19.5. Financial
Analysis
18.19.6. SWOT
Analysis
18.19.7. Business
Strategies
18.20. THERADIAG
18.20.1. Company
Details
18.20.2. Company
Overview
18.20.3. Product
Offerings
18.20.4. Key
Developments
18.20.5. Financial
Analysis
18.20.6. SWOT
Analysis
18.20.7. Business
Strategies
18.21. Thermo Fisher Scientific Inc
18.21.1. Company
Details
18.21.2. Company
Overview
18.21.3. Product
Offerings
18.21.4. Key
Developments
18.21.5. Financial
Analysis
18.21.6. SWOT
Analysis
18.21.7. Business
Strategies
18.22. UTAK
18.22.1. Company
Details
18.22.2. Company
Overview
18.22.3. Product
Offerings
18.22.4. Key
Developments
18.22.5. Financial
Analysis
18.22.6. SWOT
Analysis
18.22.7. Business
Strategies
18.23. Other
Industry Participants
19. Key
Findings
Note: This ToC is tentative
and can be changed according to the research study conducted during the course
of report completion.
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
Why Absolute Markets Insights?
An effective strategy is the entity that influences a business to stand out of the crowd. An organization with a phenomenal strategy for success dependably has the edge over the rivals in the market. It offers the organizations a head start in planning their strategy. Absolute Market Insights is the new initiation in the industry that will furnish you with the lead your business needs. Absolute Market Insights is the best destination for your business intelligence and analytical solutions; essentially because our qualitative and quantitative sources of information are competent to give one-stop solutions. We inventively combine qualitative and quantitative research in accurate proportions to have the best report, which not only gives the most recent insights but also assists you to grow.